Compare XNET & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XNET | NNNN |
|---|---|---|
| Founded | 2003 | 2021 |
| Country | China | Germany |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.3M | 270.4M |
| IPO Year | 2011 | 2023 |
| Metric | XNET | NNNN |
|---|---|---|
| Price | $5.00 | $4.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 199.2K | 151.2K |
| Earning Date | 11-12-2026 | 10-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $0.29 | $446.57 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.52 | $4.16 |
| 52 Week High | $9.77 | $44.73 |
| Indicator | XNET | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 54.10 | 29.31 |
| Support Level | $4.76 | N/A |
| Resistance Level | $5.25 | $6.95 |
| Average True Range (ATR) | 0.16 | 0.57 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 77.59 | 10.55 |
Xunlei Ltd is a technology company providing distributed cloud services in China. It operates a powerful internet platform in China based on cloud technology to enable its users to quickly access, store, manage and consume digital media content on the internet. The company has expanded its products and services from PC-based devices to mobile devices in part through pre-installed acceleration products in mobile phones to further enlarge its user base and offer its users a wider range of access points. It provides a wide range of products and services across cloud acceleration and digital entertainment to deliver an efficient, smart and safe internet environment to its users.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).